TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36067617

Group type: EXPERIMENTAL
Intervention: Lenalidomide-dexamethasone (Rd)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 119
Study: 33293152

Group type: EXPERIMENTAL
Intervention: Vasopressor administration (N = 16)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No vasopressor administration (N = 36)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High dose vitamin C (HDVC) administration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 5% albumin (Alb) administration
Number of subjects: 52
Study: 33291053

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (P‐PN) including lipid emulsion (17% SMOFlipid® lipid)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 10% glucose (control)
Number of subjects: 72
Study: 33080839

Group type: EXPERIMENTAL
Intervention: Weekly high-dose oral vitamin D supplementation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily high-dose oral vitamin D supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 34498980

Group type: EXPERIMENTAL
Intervention: Dapivirine Gel (0.05%)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 28
Study: 35577176

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control (child safety)
Number of subjects: 212
Study: 35432382

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 1882

Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: High baseline sNfL
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Low baseline sNfL
Number of subjects: 1882
Study: 32467054

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy (RL)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 369
Study: 35379402

Group type: EXPERIMENTAL
Intervention: Dietary counselling
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal protocol (control group)
Number of subjects: 46
Study: 33223484

Group type: EXPERIMENTAL
Intervention: Physical activity (150 min of moderate activity and two sessions of resistance training/week)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (inactive patients)
Number of subjects: 106
Study: 35925745

Group type: EXPERIMENTAL
Intervention: Supportive Treatment (ST)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive-Expressive Treatment (SET)
Number of subjects: 100
Study: 32450921

Group type: EXPERIMENTAL
Intervention: Standard care supported by a reminder app (Arm A)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard care alone (Arm B)
Number of subjects: 168
Study: 33483119

Group type: EXPERIMENTAL
Intervention: eBody Project (6-week online intervention)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Education brochure (control condition)
Number of subjects: 372
Study: 35980389

Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study: 32160416

Group type: EXPERIMENTAL
Intervention: 36.25 Gy in 5 fractions delivered every other day (EOD, arm A, n = 84)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 36.25 Gy in 5 fractions delivered once a week (QW, arm B, n = 86)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Both arms (EOD and QW)
Number of subjects: 170
Study: 33832998

Group type: EXPERIMENTAL
Intervention: Non-VA acute care alert received
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Majority of care received is non-VA
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 565
Study: 33028197

Group type: EXPERIMENTAL
Intervention: Sufentanil (TCI Cet 0.48 ng ml‐1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Atropine in sufentanil-based anaesthesia
Number of subjects: 70
Study: 35472561

Group type: EXPERIMENTAL
Intervention: Probucol coated polymer free ultra-thin strut sirolimus-eluting stent (PF-SES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both stents (PF-SES and BP-SES)
Number of subjects: 70
Study: 33462485

Group type: EXPERIMENTAL
Intervention: Host genetic variation regarding microbial taxa
Number of subjects: 18340

Group type: EXPERIMENTAL
Intervention: Suggestive associations with microbial taxa
Number of subjects: 18340

Group type: EXPERIMENTAL
Intervention: Microbiome trait loci
Number of subjects: 18340
Study: 35183892

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion (1 ng/kg/min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prostacyclin infusion and Placebo
Number of subjects: 80
Study: 33638051

Group type: EXPERIMENTAL
Intervention: HiFlow/CWC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: iRoot SP/CWC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: iRoot SP/SC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HiFlow/SC
Number of subjects: 65

Group type: COMPARATOR
Intervention: AH Plus/CWC
Number of subjects: 65
Study: 35144596

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg/qd)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Metformin (1000 mg/bid)
Number of subjects: 140
Study: 33471579

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ICD therapy
Number of subjects: 0
Study: 35699959

Group type: EXPERIMENTAL
Intervention: Mobile instant messaging-delivered brief motivational interviewing
Number of subjects: 161
Study: 34275768

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg once a day for 6 months
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 33834509

Group type: EXPERIMENTAL
Intervention: MR-MtRobin method
Number of subjects: 0
Study: 33461268

Group type: EXPERIMENTAL
Intervention: Post-Traumatic Growth (PTG) dimensions: personal mental strength, interpersonal relations, new possibilities, appreciation of life
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Post-Traumatic Stress Disorder (PTSD) symptoms and reactions
Number of subjects: 277
Study: 35438179

Group type: EXPERIMENTAL
Intervention: Vaporized CBD-dominant cannabis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vaporized CBD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral CBD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epidiolex (oral formulation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Capsule (oral formulation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Syrup (oral formulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 33845158

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair plus GDMT
Number of subjects: 565

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 565
Study: 32426882

Group type: EXPERIMENTAL
Intervention: YCF supplemented with 2'‐fucosyllactose (2'‐FL)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: YCF supplemented with milk fat and intact bioactive proteins, and 2'‐FL at levels found in breast milk
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: YCF with bioactive proteins at lower levels than breast milk
Number of subjects: 461

Group type: COMPARATOR
Intervention: YCF-Ref (standard milk formula)
Number of subjects: 461
Study: 35013377

Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 82
Study: 34010805

Group type: EXPERIMENTAL
Intervention: Self-Selected Exercise Intensity (SEI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Predetermined Exercise Intensity (PEI)
Number of subjects: 37
Study: 36419071

Group type: EXPERIMENTAL
Intervention: Outpatient management (OG)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard care (HG)
Number of subjects: 97
Study: 33251538

Group type: EXPERIMENTAL
Intervention: Active music engagement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Live patient-selected music
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Music-assisted relaxation
Number of subjects: 48
Study: 34423560

Group type: EXPERIMENTAL
Intervention: Customized healing abutments (CA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Collagen matrix (CM)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both CA and CM
Number of subjects: 28
Study: 35363951

Group type: EXPERIMENTAL
Intervention: Active-treatment group (antihypertensive medications recommended for use in pregnancy)
Number of subjects: 2408

Group type: COMPARATOR
Intervention: Control group (no treatment unless severe hypertension developed)
Number of subjects: 2408

Group type: EXPERIMENTAL
Intervention: Active-treatment group
Number of subjects: 2408

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2408
Study: 34145478

Group type: EXPERIMENTAL
Intervention: Air-powder polishing (APP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Rubber-cup polishing (RCP)
Number of subjects: 23
Study: 33153515

Group type: EXPERIMENTAL
Intervention: Emotional intelligence intervention (10 sessions, 90 min each)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 111
Study: 33686102

Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic stimulation (tSMS) over the left primary motor cortex (M1) for 30 minutes
Number of subjects: 0
Study: 36309168

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 33711180

Group type: EXPERIMENTAL
Intervention: Felcisetrag 0.1 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Felcisetrag 0.3 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Felcisetrag 1.0 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Felcisetrag (all doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32308187

Group type: EXPERIMENTAL
Intervention: Gain-framed nutritional messages
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Loss-framed nutritional messages
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no food message)
Number of subjects: 161
Study: 33952812

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dietary management
Number of subjects: 31
Study: 32090491

Group type: EXPERIMENTAL
Intervention: ARCTIC trial (tight control cohort targeting stringent remission)
Number of subjects: 519

Group type: COMPARATOR
Intervention: NOR-VEAC observational study (looser definition of remission)
Number of subjects: 519
Study: 36126241

Group type: EXPERIMENTAL
Intervention: Evobrutinib 25 mg once-daily (q.d.)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg once-daily (q.d.)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg twice-daily (b.i.d.)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Evobrutinib 45 mg twice-daily (b.i.d.) with food
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 33114782

Group type: EXPERIMENTAL
Intervention: Machines only
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Free weights only
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Switching from machines to free weights
Number of subjects: 36
Study: 35819090

Group type: EXPERIMENTAL
Intervention: Suspension Training System (STS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isometric-Isotonic (ISoM-ISoT) exercises
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal life)
Number of subjects: 36
Study: 35422023

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) including citalopram, paroxetine, and sertraline
Number of subjects: 11387

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 11387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11387
Study: 32705343

Group type: EXPERIMENTAL
Intervention: Loop Ileostomy (LI)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Loop Colostomy (LC)
Number of subjects: 148
Study: 35253598

Group type: COMPARATOR
Intervention: Fluconazole 200 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg + Gentian Violet
Number of subjects: 183
Study: 33337112

Group type: EXPERIMENTAL
Intervention: Stroke characteristics (backswing and forward motion duration)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ball speed
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Spin speed
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Placement of the stroke
Number of subjects: 42
Study: 35764236

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 34258468

Group type: EXPERIMENTAL
Intervention: Propolis 500 mg twice a day for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo 500 mg twice a day for 3 months
Number of subjects: 48
Study: 32690834

Group type: EXPERIMENTAL
Intervention: Green tea extract (topical + systemic, 800 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Curcumin (topical + systemic, 950 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy (green tea extract + curcumin)
Number of subjects: 60
Study: 35977666

Group type: EXPERIMENTAL
Intervention: 6% FF‐EODF
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FF‐EODF
Number of subjects: 28

Group type: COMPARATOR
Intervention: EODF
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FF supplementation
Number of subjects: 28
Study: 34212465

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 576
Study: 32357805

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 1%, 2%, and 3% body mass (BM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of ≥2% body mass (BM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR)
Number of subjects: 14
Study: 33533873

Group type: EXPERIMENTAL
Intervention: TMVr plus GDMT
Number of subjects: 548

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 548
Study: 36339547

Group type: EXPERIMENTAL
Intervention: Alfentanil (10–25 μg/kg) combined with a fixed low dose of midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (fixed low dose)
Number of subjects: 0
Study: 34053272

Group type: EXPERIMENTAL
Intervention: Smartphone-based exercise educational care management system
Number of subjects: 452

Group type: COMPARATOR
Intervention: Traditional in-person physiotherapy rehabilitation model
Number of subjects: 452
Study: 32125434

Group type: EXPERIMENTAL
Intervention: MenACWY-Conjugate vaccine
Number of subjects: 1146

Group type: COMPARATOR
Intervention: MenACWY-Polysaccharide vaccine
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Both vaccines (MenACWY-Conjugate and MenACWY-Polysaccharide)
Number of subjects: 1146
Study: 34857382

Group type: EXPERIMENTAL
Intervention: Indocyanine green group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 33909855

Group type: EXPERIMENTAL
Intervention: G11914A variant in the NADPH gene
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (NOT_FINISHED, 'NF')
Number of subjects: 88
Study: 34873992

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT) - two weekly sessions for eight weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 28
Study: 33267860

Group type: EXPERIMENTAL
Intervention: Microenterprise intervention (text messages on job openings, educational sessions, mentoring, start-up grant, business and HIV prevention text messages)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison group (text messages on job openings only)
Number of subjects: 38
Study: 35944568

Group type: EXPERIMENTAL
Intervention: Standard tibia TKA
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Stemmed tibia TKA
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Both groups (in-group analysis)
Number of subjects: 264
Study: 33595625

Group type: EXPERIMENTAL
Intervention: Serial CT scan measurements every 6 months for 2 years
Number of subjects: 254

Group type: COMPARATOR
Intervention: Maximum transverse diameter of at least 4.25 cm
Number of subjects: 254
Study: 32527707

Group type: EXPERIMENTAL
Intervention: US-guided HIFU ablation
Number of subjects: 374

Group type: COMPARATOR
Intervention: Uterus-sparing surgery
Number of subjects: 374
Study: 35761453

Group type: COMPARATOR
Intervention: CT density measurement (Hounsfield Units) for grade 0 (no otosclerosis)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CT density measurement (Hounsfield Units) for grade 1 (inactive otosclerosis)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CT density measurement (Hounsfield Units) for grades 2 and 3 (mixed/active otosclerosis)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CT density measurement
Number of subjects: 78
Study: 34974559

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization along with routine physical therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both techniques (Instrument-assisted soft tissue mobilization and Routine physical therapy)
Number of subjects: 60
Study: 34013559

Group type: EXPERIMENTAL
Intervention: Adlerian therapy (AT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Solution-focused brief therapy (SFBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study: 33118194

Group type: EXPERIMENTAL
Intervention: PPE 25 mg/kg body weight
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PPE 50 mg/kg body weight
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (water only)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PPE treatments (both doses)
Number of subjects: 24
Study: 34674276

Group type: EXPERIMENTAL
Intervention: Composite resin adhesive with polytetrafluoroethylene tape and composite resin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Composite resin alone (without adhesive)
Number of subjects: 20
Study: 32764397

Group type: EXPERIMENTAL
Intervention: High Intensity Dynamic Resistance Exercise (HIT‐RT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (non‐training)
Number of subjects: 43
Study: 35877104

Group type: EXPERIMENTAL
Intervention: Disease-Modifying Treatments (DMTs)
Number of subjects: 665
Study: 32061121

Group type: EXPERIMENTAL
Intervention: Telephone call reminders
Number of subjects: 0
Study: 33331902

Group type: EXPERIMENTAL
Intervention: Normoxia (minimum fraction of inspired oxygen of 0.35)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyperoxia (fraction of inspired oxygen of 1.0)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyperoxia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Normoxia and Hyperoxia
Number of subjects: 100
Study: 32958026

Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-individualised physiotherapy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 0
Study: 34358723

Group type: EXPERIMENTAL
Intervention: Extra-Virgin Olive Oil (EVOO) 25 mL/d for 52 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sunflower oil (control) 25 mL/d for 52 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: EVOO
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sunflower oil (control)
Number of subjects: 73
Study: 33386840

Group type: EXPERIMENTAL
Intervention: Safety attitude
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Safety climate (mediating role)
Number of subjects: 320
Study: 32657164

Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720) for less than six months (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720) for longer than six months (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 80
Study: 32520410

Group type: EXPERIMENTAL
Intervention: SAR247799 (2.5–37.5 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR247799 (0.5–15 mg once-daily for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR247799 (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR247799 (≤5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32293033

Group type: EXPERIMENTAL
Intervention: PRIME (4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: COMBO (4 weeks)
Number of subjects: 19
Study: 35699623

Group type: EXPERIMENTAL
Intervention: MEDI0562 + durvalumab (7.5 mg MEDI0562 + 1,500 mg durvalumab)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MEDI0562 + tremelimumab (22.5 mg MEDI0562 + 225 mg tremelimumab)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MEDI0562 + durvalumab or tremelimumab
Number of subjects: 58
Study: 34822784

Group type: EXPERIMENTAL
Intervention: HTL9936, a muscarinic M1 receptor agonist, designed for cognitive loss in Alzheimer's disease.
Number of subjects: 0
Study: 35287100

Group type: EXPERIMENTAL
Intervention: Intraobserver group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Motion effects group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Different thickness cohorts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Test-retest group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Radiation group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall radiomics features
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Beam on condition
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Shape features
Number of subjects: 15